Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
552actual
Sites
108
Countries
Australia, Brazil, Canada +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-17 | actual | When the study began enrolling |
| Primary completion | 2025-11-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-04 | actual | The whole study's end, after follow-up |
| First posted | 2019-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia
Intervention
- Drug: Acalabrutinib — also filed as ACP-196
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events
measured From screening to safety follow-up period (approximately 30 days from last dose)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed